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Abstract
This is a study of the morphology and transbilayer lipid distribution of human erythrocytes treated with chlorpromazine
 . w 14 xCPZ over extended time courses. At 08C, treatment of dilauroylphosphatidyl 1- C choline-labeled erythrocytes with 120
 .mM CPZ produced an immediate stomatocytic transformation t -5 min with no concurrent change in transbilayer1r2
distribution of radiolabeled lipid, as determined by bovine serum albumin extractability. At 378C, CPZ treatment of cells
 .produced two sequential morphological effects: immediate stomatocytosis t -1 min with no concurrent change in1r2
radiolabel transbilayer distribution, followed by gradual increase in stomatocytic extent over several hours, with concurrent
redistribution of radiolabeled lipid to the inner monolayer. Cells pretreated with vanadate at 378C exhibited a triphasic
morphological response: CPZ produced immediate stomatocytosis, followed by a transient reversion to echinocytes lasting
about 2 h, before returning to stomatocytic morphologies over the next several hours. The echinocytic reversion was
accompanied by exposure of phosphatidylserine on the cell surface, as indicated by increased activation of exogenous
prothrombinase. These findings suggest that while CPZ induces transbilayer lipid redistribution over extended time periods
 .which may mediate the complex morphological transformations observed , the early stomatocytic response elicited by
addition of CPZ is not due to lipid reorganization.
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1. Introduction
 . 1Chlorpromazine CPZ is a phenothiazine drug
used in treatment of schizophrenia. Its mode of action
at the cellular level remains elusive; hence, much
effort has aimed to characterize its interaction with
)  .Corresponding author. Fax: q1 415 7234817.
1 Abbreviations: BSA: bovine serum albumin; CPZ: chlor-
promazine; DLPC: dilauroylphosphatidylcholine; DLPS: dilau-
roylphosphatidylserine; dpm: disintegrations per minute; hct:
hematocrit; MI: morphological index; PC: phosphatidylcholine;
PS: phosphatidylserine; rbc: red blood cell.
various membrane systems. For example, CPZ-mem-
brane interactions have been implicated in drug-in-
w xduced effects on mitochondrial respiration 1 and
w xsperm motility 2–4 .
 .The human erythrocyte rbc , having only one
membrane and no internal organelles, is an ideal cell
system for studying basic drug-biomembrane interac-
tions. The lipids composing the erythrocyte mem-
brane are distributed asymmetrically across the bi-
 w x .layer see Refs. 5,6 for reviews . Choline-containing
 .phospholipids, phosphatidylcholine PC and
 .sphingomyelin SM , are located mainly in the outer
monolayer of the membrane, while aminophospho-
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 .lipids, phosphatidylserine PS and phos-
 .phatidylethanolamine PE , are localized in the inner
w xmonolayer 7,8 . Lipid asymmetry control has been
implicated in such physiological functions as removal
w xof senescent erythrocytes from circulation 9–11 and
w xhemostasis 12,13 . Lipid asymmetry is actively
maintained by a vanadate-sensitive aminophospho-
 .lipid translocase flippase that transports PS and PE
w xfrom the outer to inner monolayer 14–16 . Recent
studies have produced evidence that CPZ disrupts
this asymmetry, inducing a transbilayer redistribution
 . w xscrambling of membrane lipid 17,18 .
However, the most pronounced membrane effect
seen in CPZ-treated erythrocytes is a transformation
from discoid to cupped morphology. To explain this
w xchange in shape, Sheetz and Singer 19 proposed a
bilayer couple hypothesis, whereby amphipathic
agents intercalating preferentially into the outer
monolayer of the membrane bilayer would produce a
net expansion of the outer monolayer, producing an
 .outward buckling echinocytosis or crenation , while
amphipaths intercalating preferentially into the inner
 .monolayer such as CPZ would produce an inward
 .cupping or buckling stomatocytosis . Demonstration
that the net negatively-charged phospholipids are lo-
w xcalized in the membrane inner monolayer 7,8 pro-
vided a physical rationale for the inner monolayer
disposition of cationic amphipaths like CPZ, and
direct evidence for this amphipath sequestration has
w xbeen reported 20 . While inner monolayer intercala-
tion provides a straightforward explanation for the
observed shape change, membrane effects such as
CPZ-induced lipid scrambling could play a role in the
w xshape change mechanism 18 . In this study, the
relationship between these two CPZ-induced effects
was investigated further.
2. Materials and methods
2.1. Materials
Chlorpromazine hydrochloride, sodium orthovana-
 .date, penicillin-streptomycin lyophilized powder ,
 .25% glutaraldehyde solution grade I , bovine serum
 .albumin BSA, 96–99% , Triton X-100, and dilau-
 .roylphosphatidylethanolamine DLPE were obtained
 .from Sigma Chemical Co. St. Louis, MO .
w14 xC Methyl iodide was obtained from Amersham
 .Corporation Arlington Heights, IL . Dilauroylphos-
 .phatidylserine DLPS , A23187 ionophore, and pro-
 .thrombin substrate H-Sar-Pro-Arg-pNA, HCl were
 .obtained from Calbiochem San Diego, CA . Factor
 .  .V bovine , Factor Xa human , and prothrombin
 .human were obtained from Enzyme Research Labo-
 .ratories, Inc. South Bend, IN . All other chemicals
were reagent grade. Unless otherwise noted, reagents
were used without further purification.
w 14 x 14 .Dilauroylphosphatidyl 1- C choline C-DLPC
was synthesized based on previously published meth-
w xods 21,22 . Lipid was purified on tapered silica gel
G preparative thin-layer chromatography plates
 .A n a l te c h , I n c . , N e w a r k , D E in
 .chloroformrmethanolrformic acid 65:30:4, vrv .
Final product was stored as a chloroform stock solu-
tion desiccated under argon at y208C. Periodic as-
says of the stock solution by thin-layer chromatogra-
phy showed no significant development of by-prod-
ucts or impurities.
2.2. Preparation of erythrocytes
Human blood was obtained from healthy volun-
teers by venipuncture, and collected in tubes contain-
ing citrate anticoagulant. Erythrocytes were washed 3
 .times by centrifugation 1000=g for 5 min in 150
mM NaCl, and the plasma and buffy coat were
discarded. Isolated erythrocytes were then spun at
5000=g for 5 min, resuspended in 138 mM NaClr5
mM KClr7.5 mM sodium phosphater1 mM
 .  .MgSO r5 mM glucose pH 7.4 buffer A , and4
stored at 48C until ready for use. Typically cells were
used within 10 h of collection, and all cell incuba-
tions were done in capped plastic tubes. Final ery-
 .throcyte concentrations were 20% hematocrit hct
unless otherwise noted.
2.3. Vesicle preparation
Stock lipid solutions were dried down under a
gentle stream of argon or nitrogen, then resuspended
in buffer A. Suspensions were bath-sonicated to clar-
ity, to produce small unilamellar vesicles. In experi-
ments employing PS, magnesium and glucose were
omitted from buffer A and sonication was carried out
under argon.
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2.4. Incorporation of exogenous lipid into erythro-
cytes
w14 xFor introduction of C DLPC, sonicated lipid
vesicles were added to cells and the mixture was
incubated at 378C for 30 min. Cells were then washed
by centrifugation and resuspension in buffer A to
remove any unincorporated radiolabel. Final specific
y1 activity was 36 mCi l packed cells approx. 4 mM
w14 x .C DLPC in packed cells . For DLPS incorporation,
erythrocytes were incubated with sonicated lipid vesi-
 .cles for 90 min at 378C 30–40 mM DLPS .
2.5. Treatment of erythrocytes with ˝anadate and
chlorpromazine
Vanadate and CPZ were introduced to erythrocyte
suspensions from stock solutions of phosphate-free
 .isotonic saline 5 mM vanadate and 6 mM CPZ .
Vanadate solutions were stored at room temperature,
while CPZ solutions were prepared fresh daily. Typi-
cally vanadate stock solutions were prepared fresh
monthly, although vanadate stock stored over 6
months appeared to inhibit PS translocation as com-
 .pletely as freshly made stock data not shown .
Cell suspensions in buffer A were preincubated
with 100 mM vanadate at 378C for 10–20 min.
Samples were then treated with 100–200 mM CPZ at
378C for up to 8 h. At these CPZ concentrations,
significant drug-membrane interactions are reported,
w xwith minimal cell lysis 17,19,20,23,24 . For incuba-
tions lasting 6 h or more, cell suspensions contained
antibiotics 80 to 100 U penicillinrml, 80 to 100 mg
.streptomycinrml . For 08C incubations, samples were
transferred to a 08C ice bath after vanadate preincuba-
tion, and allowed to sit at 08C for 30 to 50 min before
CPZ addition. In all experiments, control cell sample
incubation times and temperatures were identical to
incubations of experimental samples.
2.6. Treatment of erythrocytes with calcium
Calcium and ionophore were added to erythrocyte
suspensions from stock solutions. Solutions of CaCl2
 .P2H O 5–50 mM in phosphate-free isotonic saline2
were stored at 48C; solutions of A23187 ionophore in
 .ethanolrdimethyl sulfoxide 95:5, vrv were stored
at y208C.
Cell samples in 135 mM KClr5 mM NaClr15
 .mM Hepesr1.2 mM MgSO r5 mM glucose pH 7.44
 .buffer B were treated with 0.5 to 1.0 mM CaCl P2
2H O plus 5–10 mM A23187, at 378C for 60 min.2
The high potassium content of buffer B prevents cell
q w xshrinkage due to calcium-activated K efflux 25,26 .
2.7. Morphology
 .Cell samples less than 1% hct were fixed with
0.3% glutaraldehyde in buffer A or B; this fixative
concentration has been determined to provide ade-
w xquate fixation with minimal pH effects 27,28 . Upon
examination by light microscopy, individual cells
w xwere assigned a score based on shape 29–31 . Dis-
cocytes were assigned a score of 0; echinocytes were
 .assigned scores from q1 slightly echinocytic cells
 .to q5 spheroechinocytes . Stomatocytes were as-
 .signed scores from y1 monoinvaginated cells to
 .y4 spherostomatocytes . The average score of a
field of 100 cells was defined as the morphological
 . w xindex MI of that sample 30 . Typically, samples
were counted twice, in random order, to obtain an
average MI for each sample, and a standard deviation
defined by the deviations of the two individual scores
from the mean.
[14 ]2.8. Extraction of C DLPC from erythrocytes with
( [ ])BSA modified from 32
w14 xCell samples containing C DLPC were diluted
to 5% hct in buffer A with or without BSA 10%
.wrv final concentration , and incubated at 378C for
20 min. This treatment extracts radiolabeled lipids to
a steady-state maximum; samples treated with BSA
for an additional 25 min showed no additional extrac-
 .tion data not shown . For vanadate-treated samples,
all extraction buffers contained 100 mM vanadate.
Following treatment with BSA, samples were pel-
leted by centrifugation at 13600=g for 30 s, and
supernatants were removed. Pellets were lysed with
 .Triton X-100 8%, vrv , transferred to scintillation
vials, and bleached by addition of sodium azide 20
.  .mM followed by hydrogen peroxide 6–9%, vrv .
Sample vials were heated at 60–808C overnight, then
EcoLite scintillation cocktail ICN Biomedicals, Inc.,
.Irvine, CA was added to each vial, and disintegra-
 .tions per minute dpm for each pellet sample was
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determined on a liquid scintillation counter, model
 .LS 3801 Beckman Instruments, Palo Alto, CA ,
using standard quench curves. Percentages of total
radiolabel remaining in the pellets were calculated
using the formula:
%14CyPC in pellet
dpm from BSAyextracted pellet
s100=
dpm from buffer Ayextracted pellet
1 .
2.9. Prothrombinase assay for outer monolayer PS
( [ ])modified from 13,33,34
Erythrocyte samples in buffer B were incubated at
378C for 410 min, while treated concurrently with
vanadate and CPZ, or calcium as described above, for
time periods indicated in table legends. Samples then
were washed 2–3 times by centrifugation at 1000–
3000=g for 5 min at 48C, in 120 mM NaClr50 mM
 .  .Trisr6 mM CaCl P2H O pH 7.8 buffer C , ensur-2 2
ing removal of any membrane fragments. Following
dilution to 0.1% hct with a mixture of factor V 5
.  y1. nM , factor Xa 0.3 U ml , and prothrombin 1.3 U
y1.ml in buffer C, samples were incubated at 378C
for 4–6 min to produce thrombin; this reaction was
 .halted by the addition of 15 mM EDTA pH 7.4 .
After centrifugation at 13600=g for 30 s, super-
natant aliquots were combined with 100 mM pro-
thrombin substrate. Emergence of chromogenic
cleavage product was monitored at 404 nm on a
diode array spectrophotometer, model HP 8452A
 .Hewlett-Packard Co., Palo Alto, CA . Initial zero-
 .order rates of absorbance increase V were deter-max
mined using HP 89532 software Hewlett-Packard
.Co. . Readings were not converted to actual concen-
trations of exposed PS, but were used to indicate the
relative amounts of exposed PS in control and experi-
mental samples.
2.10. Determination of hemoglobin
Results of the prothrombinase assay were normal-
ized for hemoglobin concentration in each sample.
For hemoglobin determination, cell samples were
diluted 1:4 with 0.8 mM KCNr0.6 mM
 .K Fe CN r1.0 mM KH PO in Triton X-1003 6 2 4
 .0.05% vrv , allowed to react at room temperature
for at least 30 min, and analyzed spectrophotometri-
w xcally at 540 nm 35 . Supernatants of cell samples
were also assayed in this manner to determine per-
cent cell lysis per sample.
3. Results
All figures and tables report results of typical
experiments.
3.1. CPZ-induced shape change in ˝anadate-treated
erythrocytes
Cell suspensions were preincubated in buffer A in
the presence or absence of vanadate, which inhibits
active aminophospholipid translocation. Samples were
 .then treated with CPZ and incubated at 08C Fig. 1A
 .or 378C Fig. 1B . Sample aliquots were removed at
the indicated times and fixed for morphological anal-
ysis.
 .At 08C Fig. 1A , erythrocytes treated with 120
 .mM CPZ underwent a rapid t -5 min discocyte-1r2
to-stomatocyte shape transformation that stabilized
after approx. 1 h, when cells were predominantly
monoinvaginated stomatocytes. This level of stoma-
tocytosis was stable for at least 6 h at 08C. Transfor-
mation of shape occurred whether or not cells were
pretreated with 100 mM vanadate for 10 min, al-
though typically slightly less stomatocytosis was ob-
served with vanadate pretreatment. CPZ-free control
cells remained discocytic over the 7 h incubation;
vanadate-pretreated samples became slightly
echinocytic.
 .At 378C Fig. 1B , samples treated with vanadate
or CPZ alone exhibited shape transformations very
similar to the same samples at 08C; vanadate-treated
cells crenated slightly, and CPZ-treated cells devel-
oped rapid stomatocytosis that was slightly greater
than at 08C. However, when CPZ was added to
vanadate-pretreated cells at 378C, a triphasic shape
progression occurred, in contrast to stable stomatocy-
tosis observed at 08C. Cells at 378C first underwent a
stomatocytic transformation from MIsy0.15 to
.y0.98 within the first minute of CPZ addition. With
continued incubation, stomatocytosis was reversed,
and by 70 min after CPZ addition, cells were slightly
( )J.Y. Chen, W.H. HuestisrBiochimica et Biophysica Acta 1323 1997 299–309 303
Fig. 1. Effect of vanadate pretreatment on CPZ-induced erythro-
 .  .cyte shape change at A 08C or B 378C. Cell samples were
 .  .preincubated with solid symbols or without open symbols 100
mM vanadate for 10 min at 378C. At time zero, cells were treated
 .  .with squares or without circles 120 mM CPZ, then incubated
at the indicated temperature. Aliquots were fixed for morphologi-
cal analysis at the indicated times.
Fig. 2. Effect of vanadate posttreatment on CPZ-induced erythro-
cyte shape change at 378C. At time zero, cell samples were
 .treated with 120 mM CPZ open circles . At the indicated times,
sample aliquots were made 100 mM in vanadate, and incubated
further at 378C. The resulting morphologies were monitored
 .other symbols, as indicated .
 .echinocytic MIsq0.58 . Echinocytosis reached
maximum extent by about 2 h, at which point a
gradual stomatocytic reversion occurred, reaching MI
sy0.46 by 7 h. Similar shape progressions were
also induced when vanadate was added up to 3.5 h
 .after CPZ addition Fig. 2 ; in each case the stomato-
cytes reverted transiently toward echinocytic mor-
phology, then returned again to cupped forms.
Table 1
w14 xBack-extraction of C DLPC with BSA, from CPZ-treated human erythrocytes at 08C
aCPZ concen- Incubation MI"S.D. % dpm remaining % lysis
 .  .tration mM time min in pellet after BSA
extraction"S.D.
0 28 y0.01"0.00 11.6"0.9 0.6
b210 q0.05"0.04 11.5"0.7 n.d.
360 q0.08"0.00 11.4"0.5 2.5
120 13 y0.36"0.02 11.6"1.0 0.8
100 y0.60"0.06 11.5"0.6 n.d.
225 y0.74"0.02 11.9"0.9 1.6
345 y0.81"0.01 12.3"0.7 2.4
 .Erythrocytes were treated with CPZ at 08C for the specified incubation times, then extracted with BSA 10% wrv at 378C.
a S.D., standard deviation.
b
n.d., not determined.
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Table 2
w14 xBack-extraction of C DLPC with BSA, from CPZ-treated human erythrocytes at 378C
aCPZ concen- Incubation MI"S.D. % dpm remaining % lysis
 .  .tration mM time min in pellet after
BSA extraction"S.D.
0 18 q0.03"0.02 13.5"1.2 0.6
b180 q0.05"0.01 14.5"0.6 n.d.
380 q0.02"0.01 17.2"1.0 2.0
120 3 y0.84"0.01 13.0"1.2 2.3
95 y1.07"0.01 19.0"0.9 n.d.
245 y1.25"0.03 25.8"1.2 3.1
360 y1.26"0.07 28.1"1.1 3.6
 .Erythrocytes were treated with CPZ at 378C for the specified incubation times, then extracted with BSA 10% wrv at 378C.
a S.D., standard deviation.
b
n.d., not determined.
[14 ]3.2. C DLPC back extraction of CPZ-treated ery-
throcytes
To assess the transbilayer distribution of PC in
erythrocytes treated with CPZ at 08C and 378C, sam-
w14 xples that had been prelabeled with C DLPC were
subjected to extraction by BSA, to remove any radio-
labeled lipid from the outer monolayer of the cells
w x18,36 . Radioactivity remaining with the cell pellet
was attributed to radiolabeled lipid in the inner mono-
layer.
After short incubations, similar percentages of ra-
diolabel dpm were retained in the pellets of CPZ-free
 .  .samples at 08C 11.6% Table 1 , and at 378C
 .  .13.5% Table 2 , reflecting the normal predominant
w xouter monolayer disposition of native PC 8 . At 08C
 .Table 1 , percentage of dpm inaccessible to BSA
extraction changed very little over the course of a 6-h
incubation in the presence or absence of CPZ. In
CPZ-free cell samples, morphologies remained dis-
coid throughout the incubation, while the percentage
of pellet-associated dpm remained unchanged. Incu-
bation with CPZ produced stomatocytosis to MIs
y0.81 after 345 min, a change that was not accom-
panied by a significant increase in pellet-associated
counts. This suggests that at 08C, very little transbi-
Table 3
w14 x  .Effect of vanadate on extraction of C DLPC from CPZ-treated human erythrocytes 378C
a . Incubation MI"S.D. % dpm remaining in % lysisConcentration mM
 .time min pellet after BSAVanadate CPZ
extraction"S.D.
0 0 115 y0.04"0.02 11.9"0.7 0.8
435 y0.08"0.06 13.8"0.7 0.8
b0 120 85 y0.96"0.10 16.8"1.0 n.d.
400 y1.44"0.11 24.1"1.1 2.3
100 0 135 q0.20"0.01 12.6"0.6 0.8
450 y0.04"0.01 16.4"0.7 0.9
100 120 100 q0.80"0.12 18.2"1.3 2.5
415 y0.91"0.01 28.6"1.0 2.6
Erythrocytes were pretreated with vanadate for 10 min at 378C, treated with CPZ at 378C for the specified incubation times, then
 .extracted with BSA 10% wrv at 378C.
a S.D., standard deviation.
b
n.d., not determined.
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layer redistribution of PC occurred as cells became
more stomatocytic.
 .At 378C Table 2 , PC redistribution was apparent
over time. Initially, there was no difference in rela-
tive radiolabel extractability between CPZ-free and
CPZ-treated samples. In CPZ-free samples, pellet-as-
sociated dpm increased from 13.5% of total counts at
18 min to 17.2% at 380 min, while morphologies
remained discoid. This suggests a slow redistribution
of radiolabel from the outer to inner monolayer at
378C over this time course, indicative of passive
w xDLPC flip-flop 37,38 . With CPZ treatment, the
fractional increase in pellet-associated dpm was much
greater, rising from 13.0% of total counts after 3 min
of CPZ treatment to 28.1% after 360 min of treat-
ment. This indicates a drug-induced acceleration of
PC transbilayer redistribution. Concurrently, cells be-
came slightly more stomatocytic. However, CPZ-in-
duced stomatocytosis had already developed at the
 .earliest extraction time MIsy0.84 , while the
shape change became only slightly more extensive
with the following hours of incubation. Thus, as at
08C, there is no apparent kinetic correlation between
CPZ-induced PC scrambling and stomatocytosis.
Vanadate had no significant independent effect on
w14 x  .the extractability of C DLPC at 378C Table 3 .
After 7.5 h of incubation, cells treated with 100 mM
vanadate alone showed a slight increase in unex-
tractable dpm compared to cells without vanadate,
consistent with a previous report of vanadate-induced
w xredistribution of PC in the bilayer 39 . Vanadate also
did not have a significant effect on net radiolabel
redistribution induced by CPZ. After 1.5–2.5 h of
incubation at 378C in the absence of vanadate, the
unextractable PC fraction was 5% greater in the
CPZ-treated sample than in the CPZ-free control
 .control, 11.9%; CPZ sample, 16.8% . A similar
small increase was observed in samples pretreated
 .with vanadate control, 12.6%; CPZ sample, 18.2% .
After 6.5–7.5 h of incubation, pellet-associated counts
in each of the CPZ-treated samples had risen by
10–13% of the total, relative to the corresponding
control i.e., the fractional increase in pellet-associ-
ated counts was similar in the presence or absence of
.vanadate . These results are consistent with a similar
study of vinblastine-invaginated cells, in which vana-
date was not observed to affect the transbilayer distri-
w xbution of spin-labeled sphingomyelin probes 18 .
In all samples, percent cell lysis increased over
 .time, but never exceeded 4% Tables 1–3 . However,
w14 xsince C DLPC extractability tended to decrease
over time, this level of lysis did not compromise the
qualitative interpretation of these results. Decreased
accessibility of radiolabel with time was not due to
BSA degradation; extended incubations of control
w14 xsamples enriched with 50% more C DLPC showed
Table 4
Prothrombinase assay for outer monolayer PS in vanadaterCPZ-treated erythrocytes at 378C
b 3 c .Treatment Incubation time MI"S.D. AUrs"S.D. =10
2q  .qCPZ or Ca min
a100 mM vanadate 0 y0.10"0.01 2.94"0.86
a100 mM vanadateq170 mM CPZ 0 y1.22"0.08 4.53"0.04
100 q0.08"0.06 6.24"1.03
190 y0.22"0.01 5.86"0.03
410 y1.17"0.15 6.80"0.29
2q900 mM Ca q6 mM A23187 65 q3.12"0.16 19.58"1.92
All erythrocyte samples were incubated at 378C for 410 min. After 0, 220, 310, and 410 min, samples pre-equilibrated with vanadate were
treated with CPZ, then incubated further. At ts410 min, all samples were chilled and assayed for morphology and prothrombinase
 .activity normalized for hemoglobin concentration . A parallel control treated with vanadate only was incubated and assayed identically.
a Erythrocytes were preincubated with vanadate for 12 min prior to addition of CPZ.
b S.D., standard deviation.
c  .Initial zero-order increase in absorbance units per second V at 404 nm.max
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proportionately more extraction, indicating no signifi-
cant decrease in the extraction capacity of BSA in
 .this time domain data not shown .
3.3. Prothrombinase assay for outer monolayer PS in
˝anadate-pretreated, CPZ-treated erythrocytes
To assess the transbilayer distribution of endoge-
nous PS in erythrocytes, a prothrombinase assay was
used. In this assay, the presence of outer monolayer
PS initiates a coagulation cascade, resulting in a
dose-dependent liberation of chromophore from pro-
w xthrombin substrate 13,33,40 . This PS assay was
chosen over others for two reasons. First, it assays for
endogenous PS, eliminating the need for introducing
foreign PS probes such as short-chain PS homologs
.or spin labels which may not necessarily mimic the
behavior of the native species. In addition, the assay
should not remove or destroy membrane components,
thereby reducing disruptions in membrane activity
w xand integrity 33 .
Of the samples tested for outer monolayer PS
 .Table 4 , cells treated with calcium and ionophore
produced the highest rate of absorbance increase at
404 nm, indicating the most thrombin-induced cleav-
age of chromogenic substrate, and the most outer
monolayer PS. This indicates extensive scrambling of
membrane PS by calcium treatment, in agreement
w xwith previous reports 34,39,40 . Vanadate-treated
cells without CPZ showed the lowest activity of the
samples tested, producing only 15% of the activity
seen with calcium-treated cells 2.
With the addition of CPZ to vanadate-pretreated
cells at 378C, prothrombinase activity increased with
longer CPZ incubation times. Increase was apparent
even after 410 min, when activity was 50% higher
than in the sample initially exposed to CPZ but still
only 35% of the activity in the calcium-treated sam-
.ple . This suggests a continual CPZ-induced move-
ment of membrane PS from the inner to outer mono-
2 When normalized for lipid phosphate, sonicated rbc mem-
brane fragments produced a prothrombinase activation rate two-
fold higher than cells calcium-loaded under the conditions noted.
This result is offered for qualitative comparison; however, it is
probably not valid to make quantitative comparisons of prothrom-
binase activation data obtained using membranes of widely vary-
 .ing configurations M.S. Moxness, personal communication .
Fig. 3. DLPS-induced shape change of vanadate-pretreated ery-
throcytes at 378C. Cells were preincubated with 100 mM vana-
 .  .  .date for 0 min circles , 15 min triangles , or 7.5 h squares . At
time zero, 40 mM DLPS was added to each cell sample, and the
resulting morphologies were monitored over time.
layer. Cell morphologies during this time course were
typical of the triphasic shape progression seen with
CPZ-treated cells pretreated with vanadate: stomato-
 .cytic upon CPZ addition MIsy1.22 , discocytic at
 .100 min MIsq0.08 , then gradually reverting to
 .stomatocytes MIsy1.17 at 410 min . Thus, there
is no direct correlation between PS transbilayer distri-
bution and the triphasic shape progression of these
 .cells Table 4 .
3.4. DLPS-induced shape change in ˝anadate-pre-
treated erythrocytes
The role of aminophospholipid translocation in
long-term cell shape transformations was examined
in vanadate-treated cells. Erythrocytes were preincu-
bated at 378C with vanadate for 7.5 h, the time
required for vanadate-pretreated, CPZ-treated cells to
 .pass through their triphasic shape change Fig. 1B .
 .Upon DLPS addition Fig. 3 , vanadate-free cells
became slightly echinocytic after 3 min, followed by
a stomatocytic transformation that stabilized by 20
min after lipid addition. Such a shape progression is
indicative of exogenous PS incorporation into the
outer monolayer to produce echinocytes, followed by
conversion to stomatocytes as PS is transported to the
w xinner monolayer 16 .
With a 15-min vanadate preincubation followed by
 .DLPS treatment Fig. 3 , cells became highly
 .echinocytic MIsq2.02 after 6 min , and did not
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revert in shape until after 20 min of lipid incubation,
eventually dropping to MIsy0.27 after 90 min of
incubation with DLPS. With a 7.5-h vanadate prein-
cubation, cells then treated with DLPS became simi-
 .larly echinocytic MIsq1.68 after 6 min . How-
ever, after only 10 min the shapes of these cells
began to revert, returning to the morphology of vana-
 .date-free cells after 90 min MIsy1.03 . These
results indicate that with extended vanadate incuba-
tion, aminophospholipid translocase activity was par-
tially restored.
4. Discussion
The mechanism of CPZ-induced stomatocytosis in
erythrocytes has long been under study. Early work
w xsuggested 19 that stomatocytosis occurred by inter-
calation of cationic CPZ molecules into the anionic
inner monolayer of the erythrocyte membrane, result-
ing in net inner monolayer expansion and inward
 .membrane buckling the bilayer couple hypothesis .
Indeed, with a ghost membrane:aqueous phase parti-
w xtion coefficient of 1000 to 5500 23,41,42 , CPZ
should readily incorporate into erythrocyte mem-
branes. Recent studies suggest CPZ-induced effects
involving cytofacial components such as skeletal pro-
w x w xteins 43 and phosphoinositides 44 , reinforcing the
likelihood of an inner monolayer disposition.
Other studies implicate stomatocytic mechanisms
more complicated than inner monolayer intercalation,
such as inhibition of calmodulin-regulated activities
w x w x45 and CPZ-induced lipid scrambling 18 . How-
ever, CPZ-induced stomatocytosis does not appear to
be related to either of these events. In the case of
calmodulin inhibition, a number of stomatogenic am-
phipaths were found to inhibit calmodulin very little
w x46 . CPZ-induced shape change was also not corre-
lated with changes in calmodulin-dependent mem-
w xbrane protein phosphorylation 47 . Additionally,
metabolic processes such as those regulated by
.calmodulin and calmodulin-dependent kinases are
inhibited significantly at low temperatures. If calmod-
ulin inhibition were solely responsible for stomatocy-
tosis, then cooling normal cells to 08C should pro-
duce a stomatocytic response. In fact, normal cells
 .remain discoid upon cooling to 08C Fig. 1A .
The lipid scrambling mechanism provides an alter-
native based not on the bilayer distribution of CPZ,
but on redistribution of endogenous lipids. Schrier
w xand co-workers 18 propose that CPZ and related
amphipaths may induce stomatocytosis by a combina-
 .tion of 1 drug-induced bilayer scrambling of all
phospholipids, which could introduce aminophospho-
lipids to the outer monolayer without affecting mor-
 .phology; and 2 flippase-mediated selective translo-
cation of aminophospholipids back to the inner
monolayer. Absent a rapid mechanism for restoring
scrambled choline lipids to the outer monolayer, these
events result in net expansion of the inner monolayer.
Several of the present findings are inconsistent with
this hypothesis as the primary mode of CPZ action.
First, the model invokes two temperature-sensitive
processes, phospholipid flip-flop and aminophospho-
lipid translocation, both of which are inhibited
severely at 08C. If the immediate cause of CPZ-in-
duced stomatocytosis is translocation of scrambled
PS, then no CPZ effect should be apparent at 08C. In
 .fact, CPZ induces rapid t -5 min stomatocytosis1r2
at 08C, under conditions where PS transport is abol-
w x w14 xished 48 . BSA extraction of C DLPC indicates
that CPZ-induced lipid scrambling is likewise inhib-
 .ited at 08C Table 1 . While the magnitude of CPZ
 .stomatocytosis is greater at 378C than at 08C Fig. 1 ,
its occurrence at 08C cannot be attributed to phospho-
lipid redistribution.
The CPZ-induced shape effect can also be decou-
pled from lipid scrambling at 378C, by using a con-
centration of CPZ that generates only monoinvagi-
nated stomatocytes and by analyzing very early cell
 .responses Table 2 . Although both CPZ-induced re-
w14 xdistribution of C DLPC and gradual increase in
stomatocytic extent are observed over time, consis-
tent with native PC scrambling, substantial stomato-
w14 xcytosis is evident well before C DLPC redistribu-
tion can be detected. Thus, lipid scrambling does not
appear to play a role in the immediate drug-induced
shape change at 378C, but may be important in
mediating subsequent morphological events. The ear-
w xlier study 18 employed higher drug concentrations
than this work, which may accelerate the phospho-
lipid redistribution. This would complicate interpreta-
tion by superimposing several complex but kineti-
cally distinguishable responses.
The lipid redistribution mechanism is also not
supported by results of experiments using vanadate-
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pretreated erythrocytes. Earlier reports provide evi-
dence that drug-induced stomatocytosis and endocy-
w xtosis are inhibited in the presence of vanadate 18,49 .
Indeed, immediately upon addition of vanadate to
CPZ-treated cells, stomatocytosis begins to reverse
 .Fig. 2 , consistent with those reports. Such inhibition
could reflect outer monolayer expansion by drug-
scrambled aminophospholipid, trapped in the outer
w xmonolayer due to flippase inactivation 18 . However,
if cells are pretreated with vanadate and then exposed
to low concentrations of CPZ, an early immediate
stomatocytosis is observed, followed by reversion to
 .echinocytes over a 1-h interval Fig. 1B . Unless
early time-points are monitored, the overall shape
effect appears to be simple inhibition of stomatocyto-
sis. Thus, as with vanadate-free cells, the biphasic
nature of the shape change seen with vanadate pre-
treatment suggests a two-event process: intercalation
of CPZ to produce immediate stomatocytosis, fol-
lowed by general drug-induced lipid scrambling Ta-
.ble 3 and net redistribution of PS to the outer
monolayer resulting in crenation. Such accumulation
of PS in the outer monolayer is indicated by the
increased prothrombinase activity of these cells with
 .time Table 4 .
Prolonged incubations of cells with vanadate and
CPZ reveal a third phase in this complex shape
response: a gradual reversion to stomatocytes over
several hours. The mechanism behind this phase of
the shape change is not evident, as several aspects are
difficult to reconcile with any simple model. During
the time frame of the third shape response, vanadate
inhibition of the flippase is apparently partially re-
 .versed, as indicated by morphology assay Fig. 3 .
This might suggest that several hours after vanadate
and CPZ addition, flippase activity is partially re-
stored, allowing scrambled outer monolayer PS to be
slowly transported back into the inner monolayer,
producing stomatocytes 3. However, in this same ex-
tended time domain, activation of prothrombinase
 .increases slightly Table 4 , which is not consistent
with a net inward movement of PS. Hence, the
mechanism behind this part of the triphasic shape
3 CPZ is reported to reduce vanadate to vanadyl cation in free
w xaqueous solution 50 , and intracellular vanadyl acts as a rela-
w xtively inefficient flippase inhibitor 51 .
change appears to be complex, and requires further
study.
While lipid scrambling may offer a partial contri-
bution to overall CPZ-induced stomatocytosis, it ap-
pears that selective inner monolayer intercalation of
the amphipath still provides the most general expla-
nation for its morphological effects. Ongoing studies
will address preferential binding of CPZ with cytofa-
cial membrane components.
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